PAPOTTI, Mauro Giulio
 Distribuzione geografica
Continente #
NA - Nord America 24.723
EU - Europa 16.956
AS - Asia 8.688
SA - Sud America 642
OC - Oceania 275
AF - Africa 237
Continente sconosciuto - Info sul continente non disponibili 32
Totale 51.553
Nazione #
US - Stati Uniti d'America 23.915
CN - Cina 4.580
IT - Italia 3.876
IE - Irlanda 1.862
DE - Germania 1.795
FR - Francia 1.529
SE - Svezia 1.487
UA - Ucraina 1.260
GB - Regno Unito 1.011
FI - Finlandia 997
KR - Corea 924
CA - Canada 655
JP - Giappone 635
PL - Polonia 602
AT - Austria 598
IN - India 584
VN - Vietnam 449
SG - Singapore 447
BR - Brasile 368
ES - Italia 362
TR - Turchia 304
NL - Olanda 283
AU - Australia 247
DK - Danimarca 217
BE - Belgio 169
HK - Hong Kong 159
RU - Federazione Russa 158
GR - Grecia 147
MX - Messico 133
TW - Taiwan 123
CH - Svizzera 113
AR - Argentina 105
RO - Romania 98
PT - Portogallo 96
SN - Senegal 85
CO - Colombia 67
IL - Israele 60
ID - Indonesia 56
CZ - Repubblica Ceca 53
SA - Arabia Saudita 50
NO - Norvegia 49
CL - Cile 48
PH - Filippine 48
HU - Ungheria 43
PK - Pakistan 43
MY - Malesia 39
TH - Thailandia 39
EG - Egitto 34
EU - Europa 31
UZ - Uzbekistan 30
HR - Croazia 29
RS - Serbia 29
ZA - Sudafrica 28
DZ - Algeria 27
NZ - Nuova Zelanda 27
IR - Iran 25
SI - Slovenia 25
AE - Emirati Arabi Uniti 20
PE - Perù 18
EC - Ecuador 17
SK - Slovacchia (Repubblica Slovacca) 17
MU - Mauritius 13
VE - Venezuela 13
BG - Bulgaria 11
MA - Marocco 11
NG - Nigeria 11
AM - Armenia 10
IQ - Iraq 9
BY - Bielorussia 8
JO - Giordania 8
MK - Macedonia 8
TN - Tunisia 8
KZ - Kazakistan 7
GT - Guatemala 6
BA - Bosnia-Erzegovina 5
PR - Porto Rico 5
SC - Seychelles 5
SD - Sudan 5
CY - Cipro 4
LB - Libano 4
LU - Lussemburgo 4
OM - Oman 4
PY - Paraguay 4
QA - Qatar 4
SY - Repubblica araba siriana 4
BD - Bangladesh 3
EE - Estonia 3
GE - Georgia 3
KW - Kuwait 3
LK - Sri Lanka 3
LV - Lettonia 3
PA - Panama 3
CU - Cuba 2
MT - Malta 2
RE - Reunion 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BO - Bolivia 1
BS - Bahamas 1
Totale 51.528
Città #
Chandler 2.630
Beijing 2.550
Dublin 1.828
Houston 1.749
Fairfield 1.447
Ann Arbor 1.087
Ashburn 1.011
Torino 930
Wilmington 869
Jacksonville 819
Redwood City 800
Villeurbanne 751
Woodbridge 741
Seattle 614
Medford 597
Princeton 578
Vienna 563
Nyköping 515
Cambridge 514
Dearborn 488
Warsaw 481
Pisa 423
Fremont 326
Milan 299
Boston 283
Singapore 254
Shanghai 234
Turin 231
Dong Ket 225
New York 211
Boardman 191
Guangzhou 171
Toronto 168
Nanjing 165
Tokyo 163
Verona 145
Hangzhou 133
Munich 119
Rome 114
Seoul 108
Norwalk 105
Pune 105
Chicago 99
San Diego 99
Düsseldorf 93
Montréal 90
Washington 86
Brussels 83
Chengdu 79
Tappahannock 79
Helsinki 77
Falls Church 74
London 73
Los Angeles 70
Madrid 70
Wuhan 69
Hefei 67
Lachine 67
Zhengzhou 67
Phoenix 66
Taipei 66
Würzburg 66
Paris 65
São Paulo 65
Bologna 63
Mcallen 63
Mountain View 62
Shenyang 62
Jinan 57
Ottawa 57
Kunming 56
Pittsburgh 55
Silver Spring 55
Rochester 51
Istanbul 49
Ankara 48
Changsha 48
Buenos Aires 47
Central District 47
Athens 44
New Delhi 44
Dallas 42
Hebei 42
Birmingham 41
Santiago 41
Bethesda 40
Hong Kong 39
Padova 39
Amsterdam 38
Barcelona 38
Canberra 38
Philadelphia 36
Honolulu 35
Moscow 35
Chongqing 34
Florence 34
Lexington 34
Nanchang 34
Piemonte 34
Sydney 34
Totale 29.021
Nome #
The weiss score and beyond--histopathology for adrenocortical carcinoma. 1.366
The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases. 1.019
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma 1.004
Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology 859
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. 753
Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma 645
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. 633
What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms? 576
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. 494
Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied 450
Morgana acts as an oncosuppressor in chronic myeloid leukemia. 428
Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases. 416
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer 415
Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases. 406
Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients 401
Eccrine spiradenoma of the nipple: Case report, differential diagnosis and literature review 399
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart 379
Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. 363
Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas 360
Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. 356
The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index - Which is the best predictor of prostate cancer after a negative biopsy? 334
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact 326
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 314
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 313
Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer 312
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors 312
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. 312
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines 311
Mesothelioma families without inheritance of a BAP1 predisposing mutation 294
Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia 290
Detection of EGFR mutations in archival lung cancer samples by pyrosequencing 289
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations 287
Core biopsies of renal masses: a safe and accurate tool for managing all that is indeterminate 281
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations 281
An international Ki67 reproducibility study in adrenal cortical Carcinoma 274
Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. 267
Pathology of the Adrenal Cortex: a Reappraisal of the Past 25 Years Focusing on Adrenal Cortical Tumors. 264
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 262
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. 257
Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates 256
Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis 251
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. 244
Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours 243
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization 240
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 240
Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. 235
Adjuvant mitotane treatment for adrenocortical carcinoma 234
MEN1 Gene Mutation and Reduced Expression Are Associated with Poor Prognosis in Pulmonary Carcinoids 225
Morgana is a new oncosuppressor in CML 222
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 220
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. 219
Differential expression of HER2, STAT3, SOX2, IFI16 and cell cycle markers during HPV-related head and neck carcinogenesis 219
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma 218
Effects of sub-chronic nandrolone administration on hormonal adaptive response to acute stress in rats. 210
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy 207
ELOVL5 Mutations Cause Spinocerebellar Ataxia 38 201
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 201
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up 198
YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study 196
ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 190
Differentiation-inducing factor 1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and Thymidylate Synthase mRNAs accumulation 186
Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma 186
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines 185
Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation 185
Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study 183
H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features data from a multi-institutional series 182
mTORC1 Complex is Significantly Over-Activated in SDHX-Mutated Paragangliomas 181
Distinctive pathological and clinical features of lung carcinoids with high proliferation index 179
Impact of COVID-19 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a tertiary referral hospital in Northwestern Italy 175
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 173
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen 171
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. 171
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 168
Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study 166
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. 162
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin 161
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 161
CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype 157
Utilility of flow cytometry as ancillary study to improve the cytologic diagnosis of thyroid lymphomas 156
A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters 154
Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas 154
ACYLATED AND UNACYLATED GHRELIN PROMOTE PROLIFERATION AND INHIBIT SERUM STARVATION- AND CYTOKINE-INDUCED APOPTOSIS OF PANCREATIC BETA-CELLS AND HUMAN ISLETS. INVOLVEMENT OF cAMP/PKA, ERK1/2 AND PI3K/AKT SIGNALING 153
Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas. 152
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme. 144
Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. 143
Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal 143
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 140
Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract 140
SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: A multicenter interobserver variation analysis using virtual microscopy: A Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T) 136
mTOR/p70S6K in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. 134
Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. 134
Classification of pulmonary neuroendocrine tumors: New insights 133
Synergistic activation upon MET and ALK coamplification sustains targeted therapy in sarcomatoid Carcinoma, a deadly subtype of lung cancer 129
Current state-of-the-art therapy for advanced squamous cell lung cancer 127
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 126
Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era 126
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer 123
PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid 123
RFamide peptides 43RFa and 26RFa both promote survival of pancreatic β-cells and human pancreatic islets but exert opposite effects on insulin secretion. 121
Thymidylate synthase expression in large cell carcinoma ofthe lung 120
Totale 28.114
Categoria #
all - tutte 137.115
article - articoli 0
book - libri 0
conference - conferenze 9.819
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 146.934


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019588 0 0 0 0 0 0 0 0 0 0 0 588
2019/20208.885 451 445 593 949 748 1.441 1.002 655 856 713 615 417
2020/20216.665 578 455 587 389 591 495 602 376 667 623 489 813
2021/20226.619 336 377 372 474 358 349 478 412 287 469 1.334 1.373
2022/20239.107 924 626 227 882 857 2.266 714 576 974 249 460 352
2023/20244.385 588 779 340 276 323 591 208 276 58 278 399 269
Totale 53.427